Jefferies Maintains Buy on Roivant Sciences, Raises Price Target to $52

Benzinga Newsdesk www.benzinga.com Positive 80.8%

Neg 0% Neu 0% Pos 80.8%

Jefferies analyst Dennis Ding maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $42 to $52.